Kairos Pharma, Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| KAPA | PPBT | CRIS | PCSA | ATORX.ST | INAB | |
|---|---|---|---|---|---|---|
| Market cap | 1.66M | 1.98M | 7.41M | 5.41M | 38.89M | 9.18M |
| P/E (TTM) | — | — | 0.8 | — | — | — |
| Forward P/E | -0.1 | -1.2 | -0.2 | -0.5 | -0.1 | -1.0 |
| Price/book | 0.4 | 0.1 | 0.5 | -17.0 | 0.3 | 0.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −92.33% | −85.52% | −97.50% | −77.18% | −99.41% | −41.72% |
| Today | −3.03% | +2.97% | +55.48% | −0.26% | +1.87% | −2.02% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All KAPA news ›Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in…
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in…
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th…
Kairos Pharma’s ENV-105 Shows Significant Survival Benefit in Prostate Cancer Trial
citybuzz - Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on addressing drug resistance in cancer, announced interim efficacy results for its lead candidate ENV-105 at th
KAPA: Kairos Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Kairos amended its Helena equity line: pricing cut to 97% of VWAP, pricing period shortened to one day, option extended to Dec 31, 2028. Plus members following KAPA got this by push and email at 11:50:37 ET - 1.4s after publication.…
Kairos Pharma Announces 1-for-7 Reverse Stock Split
Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of…
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
Combination Targets a $570M–$1.3B Addressable Global Market; ENV-105 Phase 2 Data Show 86% Clinical Benefit Rate in Resistant mCRPC Kairos Pharma, Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer…
KAPA: SEC Form 8-K filed by Kairos Pharma Ltd.
Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. KAPA: SEC Form 8-K filed by Kairos…
Kairos Pharma Receives GHP Magazine's Healthcare & Pharmaceutical Award
Company selected for the Leaders in Drug Resistance Development award Kairos Pharma Ltd. (NYSE:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, announces that it has been named a winner of the…
Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
Kairos presents ENV-105 interim Phase 2 data at Cancer R&D 2026: PFS 17.7 vs 2 months with apalutamide alone (P=0.0008). Plus members following KAPA got this by push and email at 11:45:01 ET - 1.4s after publication. Written by Quantisnow…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- quantisnow.com10
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.